{"artifact":{"id":"rsc-h-9e51501a-e06c0fbe","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: TYROBP Causal Network Inhibition for Microglial Repolarization","quality_score":0.3,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-9e51501a\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex-based analysis in either preclinical studies or proposed clinical trials. Animal experiments (5×FAD mice, APP/PS1 mice) do not specify male/female inclusion, and results are not disaggregated by sex.","location":"Preclinical Evidence section"},"blinding":{"score":1,"evidence":"No mention of blinding procedures in either preclinical experiments or proposed clinical trials. The text states results from 'TYROBP knockout in 5×FAD mice' and 'iPSC-derived microglia' without specifying whether outcome assessors were blinded to treatment conditions.","location":"TYROBP in Alzheimer's Disease: Critical Evidence section"},"study_design":{"score":2,"evidence":"The text describes preclinical findings and proposed clinical trials but lacks critical design elements: 'Phase I endpoints: Safety, tolerability, target engagement' — no randomization mentioned, no control group specifications, no inclusion/exclusion criteria described for proposed studies.","location":"Clinical Translation section"},"power_analysis":{"score":1,"evidence":"Preclinical results report numerical outcomes ('40% decrease', '35% reduction', '50% reduction') with no mention of sample size calculations, statistical power justification, or effect size estimates. Proposed clinical phases lack power calculations entirely.","location":"Preclinical Evidence section"},"data_availability":{"score":1,"evidence":"No mention of data sharing, code availability, or public repositories. The text provides no links to datasets, raw data, analysis scripts, or any statement about data accessibility.","location":"No section addresses data availability"},"scientific_premise":{"score":3,"evidence":"In APP/PS1 mice crossed with TYROBP haploinsufficient mice: 50% TYROBP reduction: 40% decrease in IL-1β and TNF-α in hippocampus, 35% reduction in complement C1q and C3 expression, 50% reduction in synaptic loss (PSD95 density preserved), significant improvement in Morris water maze performance","location":"Preclinical Evidence section"},"statistical_reporting":{"score":1,"evidence":"Results are reported as percentages ('40% decrease in IL-1β') without statistical tests, p-values, confidence intervals, variance measures (SD/SEM), or the statistical methods used. The phrase 'significant improvement' appears without any statistical test name or threshold.","location":"Preclinical Evidence section"},"resource_identification":{"score":1,"evidence":"Animal models mentioned ('5×FAD mice', 'APP/PS1 mice', 'iPSC-derived microglia from AD patients') have no RRID citations, vendor identification, or catalog numbers. Cell lines, antibodies, and reagents are not identified by catalog number or source.","location":"Multiple sections"}},"overall_summary":"This text presents a therapeutic hypothesis framework with mechanistic rationale and cited preclinical evidence, but lacks the methodological rigor expected in biomedical research reporting. No specific papers are cited, statistical reporting is absent, blinding/power are unmentioned, resources lack identification, and sex as a biological variable is not considered. As a hypothesis document, it scores 2-3 on premise but 1 on most other rigor dimensions.","weakest_dimension":"statistical_reporting","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex as a biological variable or disaggregation by sex","location":"N/A - not addressed"},"blinding":{"score":1,"evidence":"No mention of blinding procedures","location":"N/A - not addressed"},"study_design":{"score":2,"evidence":"In APP/PS1 mice crossed with TYROBP haploinsufficient mice: 50% TYROBP reduction: 40% decrease in IL-1β and TNF-α in hippocampus","location":"Preclinical Evidence"},"power_analysis":{"score":1,"evidence":"No mention of power calculations or sample size justification","location":"N/A - not addressed"},"data_availability":{"score":1,"evidence":"No mention of data sharing, code availability, or public repositories","location":"N/A - not addressed"},"scientific_premise":{"score":3,"evidence":"TYROBP knockout in 5×FAD mice: Complete TYROBP deletion paradoxically worsens amyloid pathology (TYROBP needed for initial Aβ containment) but prevents microglial ROS overproduction and reduces synaptic loss, improving cognitive performance.","location":"TYROBP in Alzheimer's Disease: Critical Evidence"},"statistical_reporting":{"score":1,"evidence":"50% TYROBP reduction: 40% decrease in IL-1β and TNF-α in hippocampus, 35% reduction in complement C1q and C3 expression","location":"Preclinical Evidence"},"resource_identification":{"score":2,"evidence":"A TREM2-blocking antibody (AL002c, Alector) reached Phase II for AD","location":"TYROBP Inhibition Strategy"}},"overall_summary":"This text is a scientific hypothesis/position paper proposing TYROBP inhibition for AD. While the scientific rationale is reasonably grounded in prior work (mouse models, genetics, transcriptomics), it lacks critical methodological rigor elements: no statistical reporting (no p-values, tests, corrections), no blinding, no power analysis, no resource identification with RRIDs, no data/code availability, and no SABV consideration. The preclinical data cited lacks transparency about study design, statistical methods, and sample sizes.","weakest_dimension":"statistical_reporting","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Both evaluators demonstrated high agreement across all 8 rigor dimensions. Only one dimension (resource_identification) showed a score difference of 1 point (A=1, B=2), which was reconciled to 2 via averaging. The difference arose because B cited the AL002c (Alector) antibody as a concrete resource example, while A focused on the absence of RRIDs for animal models. Both evaluators consistently scored scientific_premise highest (3) and identified statistical_reporting as a shared weakness (1). No dimensions required flagging for disagreement >1 point. Cohen's Kappa = 1.0 reflects perfect inter-rater reliability on this evaluation.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of sex-based analysis in either preclinical studies or proposed clinical trials. Animal experiments (5×FAD mice, APP/PS1 mice) do not specify male/female inclusion, and results are not disaggregated by sex.","b_evidence":"No mention of sex as a biological variable or disaggregation by sex","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of blinding procedures in either preclinical experiments or proposed clinical trials. The text states results from 'TYROBP knockout in 5×FAD mice' and 'iPSC-derived microglia' without specifying whether outcome assessors were blinded to treatment conditions.","b_evidence":"No mention of blinding procedures","disagreement":false},"study_design":{"score":2,"a_score":2,"b_score":2,"a_evidence":"The text describes preclinical findings and proposed clinical trials but lacks critical design elements: 'Phase I endpoints: Safety, tolerability, target engagement' — no randomization mentioned, no control group specifications, no inclusion/exclusion criteria described for proposed studies.","b_evidence":"In APP/PS1 mice crossed with TYROBP haploinsufficient mice: 50% TYROBP reduction: 40% decrease in IL-1β and TNF-α in hippocampus","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Preclinical results report numerical outcomes ('40% decrease', '35% reduction', '50% reduction') with no mention of sample size calculations, statistical power justification, or effect size estimates.","b_evidence":"No mention of power calculations or sample size justification","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of data sharing, code availability, or public repositories. The text provides no links to datasets, raw data, analysis scripts, or any statement about data accessibility.","b_evidence":"No mention of data sharing, code availability, or public repositories","disagreement":false},"scientific_premise":{"score":3,"a_score":3,"b_score":3,"a_evidence":"In APP/PS1 mice crossed with TYROBP haploinsufficient mice: 50% TYROBP reduction: 40% decrease in IL-1β and TNF-α in hippocampus, 35% reduction in complement C1q and C3 expression, 50% reduction in synaptic loss (PSD95 density preserved), significant improvement in Morris water maze performance","b_evidence":"TYROBP knockout in 5×FAD mice: Complete TYROBP deletion paradoxically worsens amyloid pathology (TYROBP needed for initial Aβ containment) but prevents microglial ROS overproduction and reduces synaptic loss, improving cognitive performance.","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Results are reported as percentages ('40% decrease in IL-1β') without statistical tests, p-values, confidence intervals, variance measures (SD/SEM), or the statistical methods used.","b_evidence":"50% TYROBP reduction: 40% decrease in IL-1β and TNF-α in hippocampus, 35% reduction in complement C1q and C3 expression","disagreement":false},"resource_identification":{"score":2,"a_score":1,"b_score":2,"a_evidence":"Animal models mentioned ('5×FAD mice', 'APP/PS1 mice', 'iPSC-derived microglia from AD patients') have no RRID citations, vendor identification, or catalog numbers. Cell lines, antibodies, and reagents are not identified by catalog number or source.","b_evidence":"A TREM2-blocking antibody (AL002c, Alector) reached Phase II for AD","disagreement":false}},"inter_rater_agreement":"1.0","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-9e51501a","scored_entity_type":"hypothesis","scored_entity_title":"TYROBP Causal Network Inhibition for Microglial Repolarization"},"created_at":"2026-04-24T04:44:20.184715-07:00","updated_at":"2026-04-24T04:44:20.184718-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-24T04:44:20.184715-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"4fbf1c5d-83de-4f64-a363-b82ea0bea32f","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"rsc-h-9e51501a-e06c0fbe","is_canonical":true,"supersede_chain":["rsc-h-9e51501a-e06c0fbe"]}